CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 48 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2019. The put-call ratio across all filers is 0.43 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $16 | -97.0% | 491 | -95.9% | 0.00% | -100.0% |
| Q4 2022 | $539 | -99.8% | 12,102 | +35.7% | 0.00% | – |
| Q3 2022 | $250,000 | -43.9% | 8,916 | -46.1% | 0.00% | – |
| Q2 2022 | $446,000 | +7.0% | 16,546 | +35.0% | 0.00% | – |
| Q1 2022 | $417,000 | -16.8% | 12,252 | -5.7% | 0.00% | -100.0% |
| Q4 2021 | $501,000 | -60.6% | 12,990 | -64.8% | 0.00% | 0.0% |
| Q3 2021 | $1,270,000 | +2.4% | 36,911 | -0.5% | 0.00% | 0.0% |
| Q2 2021 | $1,240,000 | +2284.6% | 37,111 | +1357.6% | 0.00% | – |
| Q1 2021 | $52,000 | -89.5% | 2,546 | -91.0% | 0.00% | -100.0% |
| Q4 2020 | $493,000 | +94.9% | 28,144 | +65.0% | 0.00% | – |
| Q3 2020 | $253,000 | -68.9% | 17,062 | -72.7% | 0.00% | -100.0% |
| Q2 2020 | $813,000 | +2610.0% | 62,592 | +356.7% | 0.00% | – |
| Q4 2019 | $30,000 | +275.0% | 13,705 | +227.6% | 0.00% | – |
| Q3 2019 | $8,000 | -46.7% | 4,183 | -27.4% | 0.00% | – |
| Q2 2019 | $15,000 | +275.0% | 5,765 | +596.3% | 0.00% | – |
| Q1 2019 | $4,000 | – | 828 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,017,524 | $20,961,000 | 7.56% |
| Octagon Capital Advisors LP | 561,398 | $11,565,000 | 4.36% |
| COMMODORE CAPITAL LP | 369,951 | $7,621,000 | 3.04% |
| Opaleye Management Inc. | 985,000 | $20,291,000 | 2.98% |
| VR Adviser, LLC | 1,240,610 | $25,557,000 | 2.77% |
| TSP Capital Management Group, LLC | 359,229 | $7,400,000 | 2.61% |
| RTW INVESTMENTS, LP | 3,908,947 | $80,524,000 | 1.26% |
| Ghost Tree Capital, LLC | 250,000 | $5,150,000 | 1.21% |
| Tri Locum Partners LP | 196,672 | $4,051,000 | 1.00% |
| Redmile Group, LLC | 3,387,788 | $69,788,000 | 0.98% |